RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	12	5	9	121	285	172
Market Cap Growth	-83.75%	-47.92%	-92.58%	-57.64%	65.49%	45.85%
Enterprise Value	6	-1	96	171	342	128
PE Ratio	0.09	0.20	-0.12	-1.24	-3.74	-4.07
PS Ratio	1.77	0.71	0.14	1.41	4.43	27.37
PB Ratio	5.58	2.25	-0.18	13.60	20.56	2.87
P/FCF Ratio	-0.13	-0.13	-0.30	-1.85	-5.82	-4.21
P/OCF Ratio	-0.13	-0.13	-0.31	-1.86	-5.87	-4.23
EV/Sales Ratio	0.97	-0.08	1.55	1.99	5.32	20.37
EV/EBITDA Ratio	0.43	-0.04	-2.76	-2.71	-6.23	-3.05
EV/EBIT Ratio	0.50	-0.04	-2.23	-2.10	-5.37	-2.97
EV/FCF Ratio	0.01	0.01	-3.26	-2.62	-6.98	-3.13
Debt / Equity Ratio	0.57	0.57	-2.53	9.89	6.27	0.06
Debt / EBITDA Ratio	0.08	0.08	-3.54	-1.39	-1.58	-0.09
Debt / FCF Ratio	-0.03	-0.03	-4.18	-1.35	-1.77	-0.09
Quick Ratio	0.47	0.47	0.36	0.86	0.80	4.62
Current Ratio	0.84	0.84	0.44	1.09	0.96	5.01
Asset Turnover	0.07	0.07	0.38	0.43	0.39	0.11
Interest Coverage	-	-	-1.49	-4.89	-5.10	-
Return on Equity (ROE)	-103.20%	-103.20%	256.90%	-379.40%	-252.10%	-108.00%
Return on Assets (ROA)	26.30%	26.30%	-44.00%	-49.40%	-46.20%	-76.20%
Return on Capital (ROIC)	389.64%	389.64%	-57.67%	-83.92%	38.69%	-67.70%
Earnings Yield	207.32%	512.73%	-800.21%	-80.97%	-26.73%	-24.57%
FCF Yield	-310.61%	-768.17%	-328.07%	-53.98%	-17.19%	-23.76%
Buyback Yield / Dilution	-100.19%	-100.19%	-36.43%	-32.67%	-24.33%	-33.36%
Total Shareholder Return	-100.19%	-100.19%	-36.43%	-32.67%	-24.33%	-33.36%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).